# Yohann Loriot

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yohann-loriot/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,435 |
| Field | Bladder and Urothelial Cancer Treatments |
| h-index | 79 |
| i10-index | 315 |
| Last Known Institution | Université Paris-Sud |
| OpenAlex ID | https://openalex.org/A5027991868 |
| ORCID iD | https://orcid.org/0000-0002-8338-1739 |
| Works | 1,131 |

## Researcher papers

- [Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors](https://scholariq.org/papers/gut-microbiome-influences-efficacy-of-pd-1-based-immunotherapy-against/)
- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial](https://scholariq.org/papers/atezolizumab-in-patients-with-locally-advanced-and-metastatic-urothelial/)
- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma](https://scholariq.org/papers/avelumab-maintenance-therapy-for-advanced-or-metastatic-urothelial-carcinoma/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial](https://scholariq.org/papers/genomic-and-transcriptomic-profiling-expands-precision-cancer-medicine-the/)
- [TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors](https://scholariq.org/papers/trophy-u-01-a-phase-ii-open-label-study-of-sacituzumab-govitecan-in-patients/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†](https://scholariq.org/papers/eau-esmo-consensus-statements-on-the-management-of-advanced-and-variant-bladder/)
- [Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers](https://scholariq.org/papers/crizotinib-resistant-i-ros1-i-mutations-reveal-a-predictive-kinase-inhibitor/)

## Researcher topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Université Paris-Sud](https://scholariq.org/institutions/universite-paris-sud/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.